GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are:
1. Does semaglutide lower the number of alcoholic beverages participants drink alcohol per month?
2. Does semaglutide lower the number of cigarettes participants smoke per month?
3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco?
Researchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week.
Participants will:
1. Take semaglutide for 3 months
2. Visit the research clinic 3 times for checkups and tests
3. Provide blood samples, stool samples, and saliva samples for tests.
Phase:
PHASE4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) Norton Healthcare University of Louisville